Research

The key partners for the new research facility will be announced in the coming months

A 50 milligrams dose of TruCBN significantly improved sleep disturbances

In clinical settings, a racemic mixture of both R and S ketamine is commonly used

The findings are particularly significant for depression and related mental health conditions, according to MindBio researchers.

The study estimated up to 30 per cent of schizophrenia cases in young men could have been prevented by averting cannabis use disorder

After three hours, researchers noticed that the effect wore off and the mice recovered their fertility

The companies are already planning a second set of experiments with the goal of progressing to flight tests

Initial prescription formulations will also include a social anxiety remedy

64% of respondents haven't been saving money for gifts but expect to spend over $500 this season

The most efficient cannabinoid was THC, followed by CBDV, CBD, CBC, CBN and CBD

Despite an economic downturn in many industries this year, clean energy continues to be an attractive investment

New phase I study will be held at MAC Clinical Research in Manchester, England next year

34% of pregnant participants reported using cannabis to treat symptoms

North America will continue to dominate the market during the forecast period

Although the effects were weaker and more prone to bias, microdoses also seemed to be efficient in pain management

Company will collaborate with Premier Consulting as regulatory partner and utilize Zylö Therapeutics Z-Pod technology

DMT is the backbone structure of popular psychedelics being tested for medical purposes such as psilocin and LSD

New study also suggests that plant-derived medicines can reduce inflammation and improve mental health

UK Cannabis Center will investigate the potential of the plant for treating medical conditions

Market growth will be driven by a variety of factors

New study will compare the effects of MDA and MDMA in humans for the first time

Increasing rates of stress, insomnia and other sleep disorders around the globe will propel market growth

Legalization of cannabis in multiple countries such as the U.S., Canada and Australia will be primary driver of market growth

Study will evaluate psilocybin efficacy in healthcare workers with mental health challenges related to pandemic

Recent demand for sleep devices is partially attributed to rising rates of anxiety disorders in American population

New clinical research will assess efficacy of IV formulation for the treatment of strokes

The authors say the results of this new analysis further support caution against using cannabis during pregnancy

The study assessed differences between psilocybin and escitalopram on common signs in MDD

New statistics from CBD producer show that older generations prefer cannabinoid over traditional medicines

Melatonin decreased by 14% after being exposed to short wavelength light but participants saw no differences in their sleep quality

New research shows that there is no scientific basis for pervading stereotype

New report outlines statistics and recent accomplishments made in the field

Clinical trial will be conducted as part of the ATMA Journey Centre's psychedelic-assisted therapist training program

Influencing policies, cataloguing proof of efficacy and assisting veterans integration processes will be ideal outcomes from partnership

Mexican clinical practice releases 'most complete and up-to-date known summary' regarding plant-derived psychoactive substance

Market growth to be driven by growing population seeking the latest reliable testing equipment

Application follows successful pre-clinical animal studies at the University of Arkansas

Growing scope of medicinal applications for CBD is a key driver of the anticipated market growth

The improvements were sustained for at least one month after the experiment

Monitoring the Future panel study supported by the NIH outlines new statistics